HK1204988A1 - Methods and compositions for preventing or treating ophthalmic conditions - Google Patents

Methods and compositions for preventing or treating ophthalmic conditions Download PDF

Info

Publication number
HK1204988A1
HK1204988A1 HK15105911.8A HK15105911A HK1204988A1 HK 1204988 A1 HK1204988 A1 HK 1204988A1 HK 15105911 A HK15105911 A HK 15105911A HK 1204988 A1 HK1204988 A1 HK 1204988A1
Authority
HK
Hong Kong
Prior art keywords
preventing
methods
compositions
treating ophthalmic
treating
Prior art date
Application number
HK15105911.8A
Other languages
English (en)
Chinese (zh)
Inventor
D Travis Wilson
K George Mooney
Peter J Oates
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Publication of HK1204988A1 publication Critical patent/HK1204988A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK15105911.8A 2012-02-22 2013-02-21 Methods and compositions for preventing or treating ophthalmic conditions HK1204988A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261601878P 2012-02-22 2012-02-22
US201261601878P 2012-02-22
US201261605576P 2012-03-01 2012-03-01
US201261605576P 2012-03-01
PCT/US2013/027175 WO2013126597A1 (en) 2012-02-22 2013-02-21 Methods and compositions for preventing or treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
HK1204988A1 true HK1204988A1 (en) 2015-12-11

Family

ID=49006208

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105911.8A HK1204988A1 (en) 2012-02-22 2013-02-21 Methods and compositions for preventing or treating ophthalmic conditions

Country Status (8)

Country Link
US (3) US20150018288A1 (https=)
EP (4) EP3281634A1 (https=)
JP (3) JP2015509500A (https=)
CN (2) CN104244964A (https=)
AU (3) AU2013222423A1 (https=)
CA (1) CA2865317A1 (https=)
HK (1) HK1204988A1 (https=)
WO (1) WO2013126597A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
ES2755134T3 (es) * 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US10221213B2 (en) 2013-12-27 2019-03-05 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
CA2941518A1 (en) * 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
JP2017512762A (ja) * 2014-03-03 2017-05-25 ステルス バイオセラピューティックス コープ 薬学的に妥当な芳香族カチオン性ペプチド及びその生成方法
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
CA3017359A1 (en) 2016-03-11 2017-09-14 Scott M. Duncan Crystalline salt forms
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
KR20210138596A (ko) * 2019-02-08 2021-11-19 오하이오 스테이트 이노베이션 파운데이션 치료제의 안구 투여용 약물전달 조성물 및 이의 사용방법
EP3771467A1 (en) * 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
WO2021216909A1 (en) * 2020-04-23 2021-10-28 Okogen, Inc. Treatment of viral conjunctivitis
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
WO2023279067A1 (en) * 2021-07-01 2023-01-05 The Regents Of The University Of California Targeting piezo1 to treat inherited and age-related macular degenerations
CN113975402B (zh) * 2021-07-19 2023-05-16 河南大学 靶向脑缺血区线粒体的神经保护药物ss31-ha-qt及其荧光探针和应用
WO2023069549A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
CN115252555B (zh) * 2022-06-07 2023-11-21 西安电子科技大学 一种膜融合性脂质体、制备方法及其在蛋白质递送中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US781405A (en) 1903-09-03 1905-01-31 Marcus A Coykendall Blank for dental plates.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2321560C (en) * 1998-03-13 2007-05-22 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6217896B1 (en) 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CN104788540B (zh) * 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
CA2781309A1 (en) * 2009-12-04 2011-06-09 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury

Also Published As

Publication number Publication date
US20150018288A1 (en) 2015-01-15
AU2017254849A1 (en) 2017-11-16
US20160361377A1 (en) 2016-12-15
AU2019203713A1 (en) 2019-06-20
EP3479839A1 (en) 2019-05-08
JP2019034947A (ja) 2019-03-07
WO2013126597A1 (en) 2013-08-29
EP3281634A1 (en) 2018-02-14
JP2017214380A (ja) 2017-12-07
US20180296630A1 (en) 2018-10-18
CN105343869A (zh) 2016-02-24
AU2013222423A1 (en) 2014-09-11
CA2865317A1 (en) 2013-08-29
EP3078384A1 (en) 2016-10-12
EP2817018A4 (en) 2015-09-23
EP2817018A1 (en) 2014-12-31
JP2015509500A (ja) 2015-03-30
CN104244964A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
HK1215934A1 (zh) 肽治疗剂及其使用方法
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
HK1209633A1 (en) Compositions and methods for treating diabetes
WO2011106106A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
MY170198A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2014161004A3 (en) Compositions and methods for the delivery of drugs to the ocular surface by contact lenses
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途
MX2013008374A (es) Apolipoproteina a-iv como un peptido antidiabetico.
MX339834B (es) Regimen terapeutico y metodos para tratar o mejorar trastornos visuales asociados a deficiencia endogena de retinoide.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
WO2011121607A3 (en) Rasagiline and its pharmaceutically acceptable salts
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof